Aloin-A

Aloin (Aloin-A; Barbaloin-A) is a natural anti-tumor anthraquinone glycoside with iron chelating activity. Aloin induces the differentiation of MC3T3-E1 cells into osteoblasts through MAPK-mediated Wnt and Bmp signaling pathways. Alkaline phosphatase (ALP) is an early marker of osteoblast differentiation, and the activity of ALP is also enhanced by Aloin. Aloin also reduces brain edema, reduces blood-brain barrier disruption and improves cortical impact injuries. Aloin is used in research into osteoporosis and traumatic brain injury (TBI)^[1][2][3][4]. In Vitro: Aloin (0.01-1 μM; 10 d) enhances the expression of osteoblast differentiation genes, Bmp-2, Runx2, and collagen 1a in a dose-dependent manner^[3].
Aloin (0.05 μM; 10 d) induces the differentiation of MC3T3-E1 cells into osteoblasts through MAPK-mediated Wnt and Bmp signaling pathways^[3].
Aloin (0.05 μM; 10 d) increases ALP activity in MC3T3-E1 cells^[3].
Aloin (10-80 μg/mL; 4.5 h) increases cell viability after biaxial stretch injury (SI), via attenuates intracellular ROS generation, inhibits changes of mitochondrial membrane potentials in mouse cerebrovascular endothelial cells (ECs)^[4].
In Vivo: Aloin (10-30 mg/kg; sinlge dose; ip 30 min before TBI injury) ameliorates traumatic brain injury (TBI) induced brain edema by controlled cortical impact injury in mice. Aloin exhibits antioxidant stress and anti-apoptotic properties in mouse brain capillary endothelial cells^[4].